Harvard Bioscience (HBIO) Gross Profit (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Gross Profit data on file, last reported at $12.2 million in Q1 2026.

• Quarterly Gross Profit changed 0.49% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.0 million (down 4.23% YoY) and the FY2025 annual result came in at $49.9 million, down 8.87% from the prior year.
• Gross Profit fell to $12.2 million in Q1 2026 per HBIO's latest filing, from $14.2 million in the prior quarter.
• Across five years, Gross Profit topped out at $18.3 million in Q1 2023 and bottomed at $11.5 million in Q2 2025.
• The 5-year median for Gross Profit is $14.2 million (2025), against an average of $14.3 million.
• The widest annual swing landed in 2022, when Gross Profit retreated 25.36%; it then rose 20.99% in 2023.
• Tracing HBIO's Gross Profit over 5 years: stood at $15.8 million in 2022, then climbed by 3.11% to $16.3 million in 2023, then declined by 14.17% to $14.0 million in 2024, then gained by 1.15% to $14.2 million in 2025, then slipped by 13.6% to $12.2 million in 2026.
• Per Business Quant, the three latest HBIO Gross Profit figures stand at $12.2 million (Q1 2026), $14.2 million (Q4 2025), and $12.0 million (Q3 2025).

Peer Comparison